Advertisement

Leishmaniasis pp 839-843 | Cite as

Vaccination and the Immunological Control of Leishmaniasis

  • James Alexander
Part of the NATO ASI Series book series (NSSA, volume 171)

Abstract

Vaccination against cutaneous leishmaniasis has long been practiced. Accounts in the literature suggest that from as early as the 19th Century children in Baghdad had been vaccinated against “Oriental Sore”, by inoculating material from active human lesions into the skin of the arm or thigh (Wenyon, 1911). In this way long-lasting immunity could be induced and the likelihood of developing disfiguring facial scars avoided. To my knowledge there has been only one vaccination study on human visceral leishmaniasis caused by L. donovani. Manson-Bahr (1961) reported that inoculation with a non-visceralising ground squirrel strain of L. donovani protected against challenge with the human parasite. The ground squirrel parasite has, in fact, been identified as L. major using biochemical and serological methods (Chance et al., 1978). However, the use of live material is subject to obvious drawbacks, scarring is inevitable at the site of inoculation and there is always the possibility of a particularly susceptible recipient developing a chronic or severe infection. The problems inherent in the use of virulent vaccines have stimulated trials using attenuated parasites or parasite fractions. Although these have proved disappointing with regard to Old World cutaneous leishmaniasis, recent field trials in South America have produced encouraging results. Using a vaccine consisting of equal parts heat-killed and sonicated promastigotes from five different parasite isolates, Mayrink et al (1985) successfully and significantly protected from infection 70% of the participants that became skin-test positive following vaccination.

Keywords

Visceral Leishmaniasis Ground Squirrel Cutaneous Leishmaniasis Leishmania Species Immunological Control 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ada, G.L. and Jones, P.D., 1987, Vaccines for the future — an update, Immunol. Cell Biol., 65:11.PubMedCrossRefGoogle Scholar
  2. Alexander, J. and Russell, D.G., 1987, A novel method of vaccination using parasite membrane antigens, This volume.Google Scholar
  3. Blackwell, J. and Ulczak, O.M., 1984, Immunoregulation of genetically controlled acquired responses to Leishmania donovani infection in mice: demonstration and characterisation of suppressor T cells in non-cure mice, Infec. Immun., 44:97.Google Scholar
  4. Chance, M.L., Schnur, L.F., Thomas, S.C. and Peters, W., 1978, The biochemical and serological taxonomy of Leishmania from the Aethiopian zoogeographical region of Africa, Ann. Trop. Med. and Parasitol., 72;533.Google Scholar
  5. Colomer-Gould, V., Quintass, L.G., Keithly, J. and Noguiera, N., 1985, A common surface antigen on amastigotes and promastigotes of Leishmania species, J. Exp. Med., 162:902.PubMedCrossRefGoogle Scholar
  6. Etges, R.J., Bouvier, J., Hoffman, R. and Bordier, L., 1985, Evidence that the major surface proteins of three Leishmania species are structurally related, Mol. Biochem. Parasitol., 14:141.PubMedCrossRefGoogle Scholar
  7. Crocker, P.R., Blackwell, J.M. and Bradley, D.J., 1984, Expression of the natural resistance gene Lsh in resident tissue macrophages, Infec. Immun., 43:1033.Google Scholar
  8. Gorczynski, R.M., 1986, Do sugar residues contribute to the antigenic determinants responsible for protection and/or abolition of protection in Leishmania infected BALB/c mice, J. Immunol., 137:1010.PubMedGoogle Scholar
  9. Gorczynski, R.M. and MacRae, S., 1982, Analysis of subpopulations of glass adherent mouse skin cells controlling resistance/susceptibility to infection with Leishmania tropica and correlation with the development of independent proliferative signals to Lyt-1+/Lyt-2+ T lymphocytes, Cell Immunol., 67:74.Google Scholar
  10. Handman, E. and Mitchell, G.F., 1985, Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis, Proc. Natl. Acad. Sci. USA., 82:5910.PubMedCrossRefGoogle Scholar
  11. Handman, E., Greenblatt, C.H. and Goding, J., 1984, An amphipathic sulphated glycoconjugate of Leishmania: characterisation with monoclonal antibodies, EMBO J., 3:1206.Google Scholar
  12. Handman, E., McConville, M.J. and Goding, J.W., 1987, Carbohydrate antigens as possible parasite vaccines, Immunol. Today, 8:181.CrossRefGoogle Scholar
  13. Hopp, T.P., 1984, Immunogenicity of a synthetic HBsAg peptide : enhancement by conjugation to a fatty acid carrier, Mol. Immunol., 31:13.CrossRefGoogle Scholar
  14. Howard, J.G., Hale, C. and Liew, F.Y., 1981, Immunological regulation of experimental cutaneous leishmaniasis IV Prophylactic effect of sublethal irradiation as a result of abrogation of suppressor T cell generation in mice genetically susceptible to Leishmania tropica, J. Exp. Med., 153:557.PubMedCrossRefGoogle Scholar
  15. Lachman, P.J., Strangeways, L., Vyakarnam, A. and Evan, G.I., 1986, Raising antibodies by coupling peptides to PPD and immunizing BCG-sensitised animals, Ciba Foundation Symp., 119:25.Google Scholar
  16. Liew, F.Y., 1986, New aspects of vaccine development, Clin. Exp. Immunol., 62:225.Google Scholar
  17. Liew, F.Y., Hale, C. and Howard, J.G., 1985, Prophylactic immunization against experimental leishmaniasis. IV subcutaneous immunization prevents the induction of protective immunity against fatal Leishmania major infection, J. Immunol., 135:2095.PubMedGoogle Scholar
  18. Manson-Bahr, P.E.C., 1961, Immunity in Kala-Azar, Trans. R. Soc. Trop. Med. Hyg., 55:550.PubMedCrossRefGoogle Scholar
  19. Mayrink, W., Williams, P., Da Costa, C.A., Magalpaes, P.A., Melr, M.N., Dias, M., Oliveira Lima, A., Michaelick, M.S.M., Ferriera Carvahlo, E., Barros, G.C., Sessa, P.A. and De Alencar, J.T.A., 1985, An experimental vaccine against American dermal leishmaniasis : experience in the State of Espirito Santo, Brazil, Ann. Trop. Med. Parasitol., 79:255.Google Scholar
  20. Morein, B., Sundquist, B., Hoglund, S., Dalsgaard, K. and Osterhaus, A., 1984, Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses, Nature, 308:457.Google Scholar
  21. Russell, D.G. and Alexander, J., 1987, Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes, J. Immunol. (submitted).Google Scholar
  22. Scott, P., Pearce, E., Natovitz, P. and Sher, A., 1987, Vaccination against cutaneous leishmaniasis in a murine model 1. Induction of protective immunity with a soluble extract of promastigotes, J. Immunol., 139:221.PubMedGoogle Scholar
  23. Watari, E., Dietzschold, B., Szoham, G. and Heber-Katz, E., 1987, A synthetic peptide induces long-term protection from lethal infection with Herpes simplex virus 2, J. Exp. Med., 165:459.PubMedCrossRefGoogle Scholar
  24. Wenyon, C.M., 1911, Oriental Sore in Baghdad, together with observations on a gregarine in Stegomyia fasciata the haemogregarine of dogs and flagellates of house flies, Parasit., 4:273.CrossRefGoogle Scholar
  25. Zanetti, M., Sercarz, E. and Jonas Salk, 1987, The immunology of new generation vaccines, Immunol. Today, 8:18.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1989

Authors and Affiliations

  • James Alexander
    • 1
  1. 1.Immunology DivisionStrathclyde UniversityGlasgowUK

Personalised recommendations